Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer
PYXS•Corporate deck highlights MICVO development program
Pyxis Oncology highlighted MICVO, a first-in-concept extracellular-targeting antibody-drug conjugate aimed at EDB+ fibronectin in the tumor matrix.
- Phase 1 dose escalation dosed 80 patients across 18 sites, testing 0.3-8 mg/kg every three weeks.
- Responses emerged from 3.6 mg/kg; 3.6-5.4 mg/kg became the focus range for continued development.
- In R/M HNSCC dose escalation, confirmed ORR was 50% with 100% disease control at 3.6 and 5.4 mg/kg.
- 5.4 mg/kg was selected for dose expansion; multiple clinical data catalysts are expected in 2H 2026.
